UNSPSC 51392805: Imazodan

This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H12N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 6PVQ5VQW24 chemically known as 3(2h)-pyridazinone, 4,5-dihydro-6-(4-(1h-imidazol-1-yl)phenyl) but generally known as imazodan, which bears US NIH Compound Identifier 55918. European Medicines Agency schedules Imazodan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08139MIG.

UNSPSC 51392805 Imazodan, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The single recent opportunity on record — Seminole County, Florida's IFB60459723LAS, posted June 30, 2026 — solicits naloxone and drug deactivation systems for community health initiatives, not imazodan, which is a veterinary pharmaceutical used in livestock treatment. The mismatch suggests either a tagging error in the sourcing system or a fundamental misalignment between the code's nominal scope and the work actually being procured under this designation.

Seminole County issued the IFB with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The procurement required electronic bid submission through the county's e-Procurement Portal, with vendors responsible for all shipping and delivery costs. Bidders had to comply with drug-free workplace certification, E-Verify requirements, and carry workers' compensation, commercial general liability, and professional liability insurance. The contract structure included an initial two-year term with a one-year renewal option and a three-month probationary period. The procurement did not specify set-aside designations for disadvantaged enterprises, though compliance with federal regulations such as the Clean Air Act and Federal Water Pollution Control Act applied, potentially reflecting FEMA funding sources. The code shows little relevant recent activity aligned with its stated pharmaceutical scope.